Infliximab in Crohn's disease: a look at the (not so distant) future

Digestive and Liver Disease

Volumn 40, Issue SUPPL. 2, 2008, Pages

  Sorrentino, D ^a   Terrosu, G ^a   Avellini, C ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Crohn's disease; Infliximab; Post operative recurrence; Strictures

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; ORNIDAZOLE; SALAZOSULFAPYRIDINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CROHN DISEASE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INDIVIDUALIZATION; INTESTINE STENOSIS; INTESTINE SURGERY; LOW DRUG DOSE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; PATIENT CARE; PATIENT SELECTION; QUALITY OF LIFE; RECURRENT DISEASE; THEORY; TIME; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; FIBROSIS; HUMANS; RECURRENCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45849117919     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(08)60531-9     Document Type: Article

References (45)

1. van Dullemen H., van Deventer S., Hommes D., Bijl H., Jansen J., Tytgat G., et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterol-ogy 109 (1995) 129-135
2. REMICADE® (infliximab) Prescribing Information. September 2006.
3. Hanauer S. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 17 (2003) 131-137
4. Oldenburg B., and Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up?. Curr Opin Gastroenterol 23 (2007) 395-399
5. Lichtenstein G. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy. Am J Gastroenterol 100 (2005) 1433-1435
6. Loftus E. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time. Am J Gastroenterol 100 (2005) 1435-1438
7. Hanauer S. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A balancing view: lifetime channeling of inflix-imab for Crohn's disease. Am J Gastroenterol 100 (2005) 1438-1439
8. Bongartz T., Sutton A., Sweeting M., Buchan I., Matteson E., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285 Review. Erratum in: JAMA 2006;295:2482.
9. Biancone L., Orlando A., Kohn A., Colombo E., Sostegni R., Angelucci E., et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 55 (2006) 228-233 Epub 2005 Aug 24.
10. Colombel J., Loftus Jr. E., Tremaine W., Egan L., Harmsen W., Schleck C., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
11. Blonski W., and Lichtenstein G. Safety of biologic therapy. Inflamm Bowel Dis 13 (2007) 769-796
12. Atzeni F., Ardizzone S., Sarzi-Puttini P., Colombo E., Maconi G., De Portu S., et al. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Aliment Pharmacol Ther 22 (2005) 453-461
13. Ferraccioli G., and Gremese E. Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers. Autoimmun Rev 3 (2004) 261-266
14. Cohen R., and Thomas T. Economics of the use of biologics in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am 35 (2006) 867-882
15. Targan S., Hanauer S., van Deventer S., Mayer L., Present D., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997) 1029-1035
16. Van Assche G., Geboes K., and Rutgeerts P. Medical therapy for Crohn's disease strictures. Inflamm Bowel Dis 10 (2004) 55-60
17. Rieder F., Brenmoehl J., Leeb S., Schölmerich J., and Rogler G. Wound healing and fibrosis in intestinal disease. Gut 56 (2007) 130-139
18. D'haens G., Van Deventer S., Van Hogezand R., Chalmers D., Kothe C., Baert F., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 116 (1999) 1029-1034
19. Vasilopoulos S., Kugathasan S., Saeian K., Emmons J., Hogan W., Otterzon M., et al. Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn's disease. Am J Gastroenterol 95 (2000) 2503
20. Toy L., Scherl E., Kornbluth A., et al. Complete bowel obstruction following initial response to infliximab therapy for Crohn's disease: A series of a newly described complication. Gastroenterology 118 (2000) A2974
21. Lichtenstein G., Olson A., Travers S., Diamond R., Chen D., Pritchard M., et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 101 (2006) 1030-1038
22. Di Sabatino A., Ciccocioppo R., Benazzato L., Sturniolo G., and Corazza G. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients. Aliment Pharmacol Ther 19 (2004) 1019-1024
23. Stenson W. Inflammatory bowel disease. In: Yamada T., Alpers D., Laine L., Owyang C., and Powell D. (Eds). Yamada textbook of gastroenterology (1999), Lippincott Williams and Wilkins, Philadelphia, PA 1775-1839
24. Geboes K., Cabooter L., and Geboes K. Contribution of morphology for the comprehension of mechanisms of fibrosis in inflammatory enterocolitis. Acta Gastro-Enterol Belg 63 (2000) 371-376
25. Mackalski B., and Bernstein C. New diagnostic imaging tools for inflammatory bowel disease. Gut 55 (2006) 733-741
26. Maconi G., Carsana L., Fociani P., Sampietro G., Ardizzone S., Cristaldi M., et al. Small bowel stenosis in Crohn's disease: clinical, biochemical and ultrasonographic evaluation of histological features. Aliment Pharmacol Ther 18 (2003) 749-756
27. Holtmann M., and Neurath M. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis 20 (2005) 1-8 Epub 2004 Sep 30.
28. Sorrentino D., Avellini C., Beltrami C., Pasqual E., and Zearo E. Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int J Colorectal Dis 21 (2006) 276-281 Epub 2005 Jun 11.
29. Sorrentino D., Terrosu G., Vadalà S., and Avellini C. Fibrotic strictures and anti TNF-a therapy in Crohn's disease. Digestion 75 (2007) 22-24 Epub 2007 Apr 10.
30. Knapp A., Mirsky F., Dillon E., and Korelitz B. Successful infliximab therapy for a duodenal stricture caused by Crohn's disease. Inflamm Bowel Dis 11 (2005) 1123-1125
31. Pallotta N., Barberani F., Hassan N., et al. Effect of infliximab on small bowel stenoses in Crohn's disease. Gastroenterology 132 (2007) S1137 (abstract)
32. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S., Present D., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody(infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 (1999) 761-769
33. Maccioni F., Bruni A., Viscido A., Colaiacomo M., Cocco A., Mon-tesani C., et al. MR imaging in patients with Crohn disease: value of T2- versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent. Radiology 238 (2006) 517-530 Epub 2005 Dec 21.
34. Sandborn W., and Feagan B. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology 127 (2004) 990-993
35. Hanauer S., Korelitz B., Rutgeerts P., Peppercorn M., Thisted R., Cohen R., et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine,mesalamine, or placebo: a 2-year trial. Gastroenterology 127 (2004) 723-729
36. Ardizzone S., Maconi G., Sampietro G., et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127 (2004) 730-740
37. Herfarth H., Tjaden C., Lukas M., Obermeier F., Dilger K., Müller R., et al. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease. Gut 55 (2006) 1525-1526
38. Marchal L., D'Haens G., Van Assche G., Vermeire S., Noman M., Ferrante M., et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 19 (2004) 749-754
39. Colombel J., Loftus Jr. E., Tremaine W., Pemberton J., Wolff B., Young-Fadok T., et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 99 (2004) 878-883
40. Biancone L., Cretella M., Tosti C., Palmieri G., Petruzziello C., Geremia A., et al. Local injection of infliximab in the postoperative recurrence of Crohn's disease. Gastrointest Endosc 63 (2006) 486-492
41. Sorrentino D., Terrosu G., Avellini C., Beltrami C., Bresadola V., and Toso F. Prevention of postoperative recurrence of Crohn's disease by infliximab. Eur J Gastroenterol Hepatol 18 (2006) 457-459
42. Sorrentino D., Terrosu G., Avellini C., and Maiero S. Infliximab with low dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch. Internal Med 167 (2007) 1804-1807
43. Caprilli R., Gassull M., Escher J., Moser G., Munkholm P., Forbes A., et al. European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 55 Suppl 1 (2006) i36-i58
44. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Car-bonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
45. Sachar D.B. Recurrence rates in Crohn's disease: predicting the future and predicting the past. Gut 55 (2006) 1069-1070